

# Ming-Huang Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8706933/publications.pdf>

Version: 2024-02-01

105  
papers

2,187  
citations

236925

25  
h-index

302126

39  
g-index

107  
all docs

107  
docs citations

107  
times ranked

4096  
citing authors

#	ARTICLE	IF	CITATIONS
1	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2015, 26, 943-949.	1.2	130
2	High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2008, 87, 475-480.	1.8	92
3	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	3.7	74
4	Clinical significance of circulating plasma DNA in gastric cancer. <i>International Journal of Cancer</i> , 2016, 138, 2974-2983.	5.1	68
5	Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. <i>Frontiers in Oncology</i> , 2020, 10, 561936.	2.8	68
6	Mutations in PI3K/AKT pathway genes and amplifications of <i>PIK3CA</i> are associated with patterns of recurrence in gastric cancers. <i>Oncotarget</i> , 2016, 7, 6201-6220.	1.8	61
7	Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis. <i>Molecular Cancer</i> , 2017, 16, 135.	19.2	59
8	Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e27186.	2.5	58
9	Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. <i>Oncotarget</i> , 2014, 5, 2372-2389.	1.8	58
10	A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. <i>Oncotarget</i> , 2017, 8, 44121-44130.	1.8	53
11	Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1783-1790.	2.5	52
12	Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw606.	4.0	51
13	DDX3 as a strongest prognosis marker and its downregulation promotes metastasis in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 18602-18612.	1.8	47
14	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072.		45
15	ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 4225-4235.	7.0	44
16	Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. <i>Oncotarget</i> , 2016, 7, 9135-9149.	1.8	43
17	Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 11.	17.0	41
18	Clinical relevance of cell-free DNA in gastrointestinal tract malignancy. <i>Oncotarget</i> , 2017, 8, 3009-3017.	1.8	38

#	ARTICLE	IF	CITATIONS
19	EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. <i>European Journal of Cancer</i> , 2017, 72, 112-123.	2.8	35
20	Effects of fine particulate matter (PM2.5) on ovarian function and embryo quality in mice. <i>Environment International</i> , 2020, 135, 105338.	10.0	34
21	Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. <i>Oncotarget</i> , 2017, 8, 41294-41304.	1.8	33
22	<i>PRKDC</i> : new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
23	Gene expression-based chemical genomics identifies heat shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. <i>Cancer</i> , 2013, 119, 293-303.	4.1	31
24	Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	31
25	Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. <i>International Journal of Biological Sciences</i> , 2016, 12, 1523-1532.	6.4	31
26	Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. <i>Journal of Gastroenterology</i> , 2013, 48, 101-108.	5.1	30
27	The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. <i>Experimental and Molecular Medicine</i> , 2017, 49, e366-e366.	7.7	29
28	High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 454-459.	1.4	26
29	Transcriptome analysis and prognosis of ALDH isoforms in human cancer. <i>Scientific Reports</i> , 2018, 8, 2713.	3.3	26
30	Lung involvement in primary Sjögren's syndrome: Correlation between high-resolution computed tomography score and mortality. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 75-82.	1.4	25
31	Prolonged facial edema is an indicator of poor prognosis in patients with head and neck squamous cell carcinoma. <i>Supportive Care in Cancer</i> , 2010, 18, 1313-1319.	2.2	24
32	Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without <i>Helicobacter pylori</i> Infection. <i>Oncologist</i> , 2019, 24, e845-e853.	3.7	24
33	The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery. <i>Cancers</i> , 2020, 12, 1517.	3.7	24
34	Expression of GOLM1 Correlates with Prognosis in Human Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 616-624.	1.5	23
35	mTOR Inhibitors in Advanced Biliary Tract Cancers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 500.	4.1	23
36	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. <i>Scientific Reports</i> , 2016, 6, 25369.	3.3	21

#	ARTICLE	IF	CITATIONS
37	&lt;p&gt;Interferon &alpha;-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 1893-1905.	1.9	21
38	Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 2573-2581.e1.	4.4	20
39	Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. Oncotarget, 2017, 8, 113444-113459.	1.8	19
40	Comparative study of the 7th and 8th AJCC editions for gastric cancer patients after curative surgery. PLoS ONE, 2017, 12, e0187626.	2.5	18
41	The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer. Cancers, 2020, 12, 2318.	3.7	18
42	Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study. Clinical and Experimental Rheumatology, 2016, 34, 1077-1084.	0.8	18
43	Upregulation of BMP-2 expression in peripheral blood mononuclear cells by proinflammatory cytokines and radiographic progression in ankylosing spondylitis. Modern Rheumatology, 2015, 25, 913-918.	1.8	17
44	Comparison of the surgical outcomes of minimally invasive and open surgery for octogenarian and older compared to younger gastric cancer patients: a retrospective cohort study. BMC Surgery, 2017, 17, 68.	1.3	17
45	Advances in Laparoscopic and Robotic Gastrectomy for Gastric Cancer. Pathology and Oncology Research, 2017, 23, 13-17.	1.9	17
46	A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors. EJNMMI Research, 2019, 9, 46.	2.5	17
47	Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. Oncotarget, 2017, 8, 103613-103625.	1.8	17
48	Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. Journal of Molecular Medicine, 2017, 95, 965-975.	3.9	16
49	Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Oncologist, 2019, 24, 1534-1542.	3.7	15
50	Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget, 2015, 6, 23594-23608.	1.8	15
51	A Prognostic Nomogram for Overall Survival of Patients After Hepatectomy for Intrahepatic Cholangiocarcinoma. Anticancer Research, 2016, 36, 4249-58.	1.1	15
52	Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center. Journal of the Chinese Medical Association, 2017, 80, 140-146.	1.4	14
53	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer, 2022, 22, 55.	2.6	14
54	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Investigational New Drugs, 2022, 40, 789-797.	2.6	14

#	ARTICLE	IF	CITATIONS
55	Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1393-1399.	0.9	13
56	Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 218.	3.7	13
57	The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 396-402.	1.1	12
58	Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	11
59	Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. <i>Oncology Letters</i> , 2018, 16, 566-572.	1.8	11
60	Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. <i>Journal of Biomedical Science</i> , 2021, 28, 29.	7.0	11
61	The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 141-147.	1.4	10
62	MART-10, the new brand of 1 $\alpha$ ,25(OH) <sub>2</sub> D <sub>3</sub> analog, is a potent anti-angiogenic agent in vivo and in vitro. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 26-34.	2.5	9
63	MART-10, a 1 $\alpha$ ,25(OH) <sub>2</sub> D <sub>3</sub> Analog, Potently Represses Metastasis of ER <sup>+</sup> Breast Cancer Cells with VEGF-A Overexpression. <i>Anticancer Research</i> , 2018, 38, 3879-3887.	1.1	9
64	Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array. <i>Clinical Epigenetics</i> , 2019, 11, 154.	4.1	9
65	Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis. <i>Life</i> , 2020, 10, 276.	2.4	9
66	The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAS and MSI Status. <i>Cancers</i> , 2020, 12, 551.	3.7	9
67	High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9116.	4.1	9
68	Treatment Patterns and Outcomes in Patients with Esophageal Cancer: An Analysis of a Multidisciplinary Tumor Board Database. <i>Annals of Surgical Oncology</i> , 2022, 29, 572-585.	1.5	9
69	A Nation-Wide Cancer Registry-Based Study of Adenosquamous Carcinoma in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0139748.	2.5	9
70	Genetic alterations in gastric cancer patients according to sex. <i>Aging</i> , 2021, 13, 376-388.	3.1	9
71	Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study. <i>Head and Neck</i> , 2017, 39, 1333-1342.	2.0	8
72	Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. <i>Vaccines</i> , 2020, 8, 703.	4.4	8

#	ARTICLE	IF	CITATIONS
73	Multicentre, phase II study of gemcitabine and Sâ€¹ in patients with advanced biliary tract cancer: TG1308 study. <i>Liver International</i> , 2020, 40, 2535-2543.	3.9	7
74	Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. <i>Clinical and Translational Immunology</i> , 2020, 9, e1145.	3.8	7
75	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. <i>Oncologist</i> , 2020, 25, e782-e788.	3.7	7
76	The clinicopathological characteristics and genetic alterations between younger and older gastric cancer patients with curative surgery. <i>Aging</i> , 2020, 12, 18137-18150.	3.1	7
77	Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4075-4075.	1.6	7
78	Overâ€¹ expression of TNN13K is associated with earlyâ€¹ stage carcinogenesis of cholangiocarcinoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 270-278.	2.7	6
79	Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. <i>Biomolecules</i> , 2021, 11, 97.	4.0	6
80	Comparison of Myeloablative and Nonmyeloablative Hematopoietic Stem Cell Transplantation for Treatment of Chronic Myeloid Leukemia. <i>International Journal of Hematology</i> , 2007, 86, 275-281.	1.6	6
81	Deltex1 suppresses T cell function and is a biomarker for diagnosis and disease activity of systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 719-728.	1.9	5
82	Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. <i>Biomolecules</i> , 2020, 10, 1377.	4.0	5
83	Pachymic acid protects oocyte by improving the ovarian microenvironment in polycystic ovary syndrome miceâ€. <i>Biology of Reproduction</i> , 2020, 103, 1085-1098.	2.7	5
84	Aldolase A and Phospholipase D1 Synergistically Resist Alkylating Agents and Radiation in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 811635.	2.8	5
85	Refractory hypercalcemia due to hyperparathyroidism in a patient with metastatic parathyroid carcinoma. <i>Journal of Cancer Research and Practice</i> , 2018, 5, 84-87.	0.2	4
86	The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 593-598.	1.4	4
87	METâ€¹RON dual inhibitor, BMSâ€¹777607, suppresses cholangiocarcinoma cell growth, and METâ€¹RON upregulation indicates worse prognosis for intraâ€¹hepatic cholangiocarcinoma patients. <i>Oncology Reports</i> , 2018, 40, 1411-1421.	2.6	4
88	The clinicopathological characteristics and prognosis of patients with node-positive gastric cancer after curative surgery. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 751-755.	1.4	4
89	Comparison of the Long-term Outcome Between Billroth-I and Roux-en-Y Reconstruction Following Distal Gastrectomy for Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1955-1961.	1.7	4
90	Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. <i>Chinese Clinical Oncology</i> , 2020, 9, 7-7.	1.2	4

#	ARTICLE	IF	CITATIONS
91	How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. <i>Cancers</i> , 2021, 13, 3536.	3.7	4
92	Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis. <i>Cell Death and Disease</i> , 2022, 13, 391.	6.3	4
93	Somatic SDHA mutations in paragangliomas in siblings. <i>Medicine (United States)</i> , 2020, 99, e22497.	1.0	3
94	Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. <i>Biomedicines</i> , 2021, 9, 885.	3.2	2
95	ASO Visual Abstract: Treatment Patterns and Outcomes for Patients with Esophageal Cancer—An Analysis of a Multidisciplinary Tumor Board Database. <i>Annals of Surgical Oncology</i> , 2021, 28, 712-713.	1.5	2
96	Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 423-428.	1.4	1
97	Mucinous gastric adenocarcinoma: A good candidate for immune therapy?. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 624-625.	1.4	1
98	Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification. <i>Frontiers in Oncology</i> , 2021, 11, 632609.	2.8	1
99	E-TPF (cetuximab, cisplatin, docetaxel, 5-FU) induction chemotherapy in locally advanced squamous cell carcinoma of oral cavity: A phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17016-e17016.	1.6	1
100	Extrahepatic cancer risk among patients with liver cirrhosis in Taiwan: A nationwide population-based study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1564-1564.	1.6	1
101	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4101-4101.	1.6	1
102	The clinicopathological characteristics and genetic alterations of gastric cancer patients according to the Lauren classification. <i>International Surgery</i> , 0, , .	0.1	1
103	A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma. <i>Medicine (United States)</i> , 2016, 95, e2565.	1.0	0
104	Genomic profiling for unfavorable carcinoma of unknown primary patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13140-e13140.	1.6	0
105	Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4120-4120.	1.6	0